Fig. 6
From: Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL
Early detection of CPMRD by NGS in surveilled patients. Serial measurements of tumor loads from five closely surveilled B-ALL cases were quantified by NGS and MCF assays. Two of the five patients (a, Pt #4 b, Pt #5) were post-transplant, and the other three patients (c, d, e) were status-post hyperCVAD chemotherapy plus Rituxan or Dasatinib. In all patients (a, b, c, d, e), MRD was not detected by either NGS or MCF after treatment (green arrow). Conversion to positive MRD (CPMRD) demonstrated by NGS was highlighted by red boxes in each patient. Discordant MRD values where there is positive NGS MRD but no detectable MRD by MCF were highlighted by red arrows (NGS-based MRD levels) and black arrows (MCF-based MRD levels). MUD, matched unrelated donor, Pt#, patient number, n, number of samples collected from each individual patient